Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Oct;16(4):417–421. doi: 10.1111/j.1365-2125.1983.tb02187.x

Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.

W G O'Callaghan, M S Laher, K McGarry, E O'Brien, K O'Malley
PMCID: PMC1428043  PMID: 6138058

Abstract

As little is known of the antihypertensive efficacy or renal haemodynamic effects of beta-adrenoceptor blocking drugs in the elderly we studied two such drugs, atenolol and nadolol, in elderly hypertensive patients. Ten patients took part in a placebo-controlled double-blind study of atenolol and 10 received nadolol in a single-blind placebo-controlled study. Treatment phases lasted 12 weeks for atenolol or 10 weeks for nadolol. Blood pressure, effective renal blood flow and glomerular filtration rate data obtained at the end of each treatment phase were analysed. Atenolol lowered mean arterial pressure (mean +/- s.e. mean) from 129.9 +/- 1.5 to 108.2 +/- 2.3 mm Hg (P less than 0.01) while it increased mean effective renal blood flow 512.5 +/- 86.6 to 646.0 +/- 116.1 ml min-1 1.73 m-2 (P less than 0.05). Nadolol reduced mean arterial pressure from 133.2 +/- 2.0 to 113.5 +/- 3 mm Hg (P less than 0.001) but reduced mean effective renal blood flow from 558.8 +/- 32.2 to 446.0 +/- 26.9 ml min-1 1.73 m-2 (P less than 0.05). Glomerular filtration did not alter significantly with either drug. We conclude that beta-adrenoceptor blocking drugs are effective antihypertensive agents in the elderly but have disparate effects on effective renal blood flow perhaps because of differences in cardioselectivity. These data suggest that comparative studies with thiazide diuretics and beta-adrenoceptor blocking drugs are warranted in elderly hypertensives.

Full text

PDF
420

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberg H. Plasma renin activity after the use of a new beta-adrenergic blocking agent (I.C.I. 66,032). Int J Clin Pharmacol. 1974 Mar;9(2):98–100. [PubMed] [Google Scholar]
  2. Bauer J. H., Brooks C. S. The long-term effect of propranolol therapy on renal function. Am J Med. 1979 Mar;66(3):405–410. doi: 10.1016/0002-9343(79)91059-3. [DOI] [PubMed] [Google Scholar]
  3. Bufano G., Piacentini L. Studio comparativo dell'influenza esercitata da agonisti e antagonisti beta-adrenergici sulla funzione renale dell'uomo normale. Minerva Med. 1969 Apr 4;60(27):1229–1232. [PubMed] [Google Scholar]
  4. Bühler F. R., Burkart F., Lütold B. E., Küng M., Marbet G., Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975 Oct 31;36(5):653–669. doi: 10.1016/0002-9149(75)90168-x. [DOI] [PubMed] [Google Scholar]
  5. Carrière S. Effect of norepinephrine, isoproterenol, and adrenergic blockers upon the intrarenal distribution of blood flow. Can J Physiol Pharmacol. 1969 Feb;47(2):199–208. doi: 10.1139/y69-034. [DOI] [PubMed] [Google Scholar]
  6. Harries J. D., Mildenberger R. R., Malowany A. S., Drummond K. N. A computerized cummulative integral method for the precise measurement of the glomerular filtration rate. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1148–1155. doi: 10.3181/00379727-140-36630. [DOI] [PubMed] [Google Scholar]
  7. Heierli C., Thoelen H., Radielovic P. Renal function following a single dose of pindolol in hypertensive patients with varying degrees of impairment of renal function. Int J Clin Pharmacol Biopharm. 1977 Feb;15(2):65–71. [PubMed] [Google Scholar]
  8. Hollenberg N. K., Adams D. F., McKinstry D. N., Williams G. H., Borucki L. J., Sullivan J. M. beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol. 1979;7 (Suppl 2):219S–225S. doi: 10.1111/j.1365-2125.1979.tb04693.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hollenberg N. K., Swartz S. L., Passan D. R., Williams G. H. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med. 1979 Jul 5;301(1):9–12. doi: 10.1056/NEJM197907053010103. [DOI] [PubMed] [Google Scholar]
  10. Ibsen H., Sederberg-Olsen P. Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sci. 1973 Feb;44(2):129–134. doi: 10.1042/cs0440129. [DOI] [PubMed] [Google Scholar]
  11. Koch-Weser J., O'Malley K., O'Brien E. Drug therapy: Management of hypertension in the elderly. N Engl J Med. 1980 Jun 19;302(25):1397–1401. doi: 10.1056/NEJM198006193022505. [DOI] [PubMed] [Google Scholar]
  12. McNay J. L., Goldberg L. I. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther. 1966 Jan;151(1):23–31. [PubMed] [Google Scholar]
  13. Niarchos A. P., Laragh J. H. Hypertension in the elderly. Mod Concepts Cardiovasc Dis. 1980 Aug;49(8):43–48. [PubMed] [Google Scholar]
  14. Pearson R. M. Methods for the assessment of the effects of drugs on renal blood flow. Br J Clin Pharmacol. 1979 Feb;7(2):129–138. doi: 10.1111/j.1365-2125.1979.tb00913.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sullivan J. M., Adams D. F., Hollenberg N. K. beta-adrenergic blockade in essential hypertension: reduced renin release despite renal vasoconstriction. Circ Res. 1976 Oct;39(4):532–536. doi: 10.1161/01.res.39.4.532. [DOI] [PubMed] [Google Scholar]
  16. Textor S. C., Fouad F. M., Bravo E. L., Tarazi R. C., Vidt D. G., Gifford R. W., Jr Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med. 1982 Sep 2;307(10):601–605. doi: 10.1056/NEJM198209023071007. [DOI] [PubMed] [Google Scholar]
  17. Waal-Manning H. J., Hobson C. H. Renal function in patients with essential hypertension receiving nadolol. Br Med J. 1980 Aug 9;281(6237):423–424. doi: 10.1136/bmj.281.6237.423-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wilcox R. G. Combination hypotensive therapy with atenolol, bendrofluazide and hydrallazine. Postgrad Med J. 1977;53 (Suppl 3):128–133. [PubMed] [Google Scholar]
  19. Zech P. Y., Labeeuw M., Pozet N., Hadj-Aissa A., Sassard J., McAinsh J. Response to atenolol in arterial hypertension in relation to renal function, pharmacokinetics and renin activity. Postgrad Med J. 1977;53 (Suppl 3):134–141. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES